Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Free Report) was the target of some unusual options trading activity on Thursday. Investors bought 5,907 call options on the stock. This represents an increase of 546% compared to the average daily volume of 914 call options.
Analyst Ratings Changes
Separately, Weiss Ratings initiated coverage on Leap Therapeutics in a research note on Wednesday. They set a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.
Get Our Latest Report on Leap Therapeutics
Leap Therapeutics Price Performance
Leap Therapeutics (NASDAQ:LPTX – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.08) EPS for the quarter.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Featured Stories
- Five stocks we like better than Leap Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- How to Invest in Biotech Stocks
- Disney’s 2026 Outlook Brightens Under Iger’s Magic Touch
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
